Nanjing Revamps Medical Trust For Centralized Drug Supply
This article was originally published in PharmAsia News
Executive Summary
Nanjing's push for medical trust, which started two years ago, will involve nine third-tier hospitals this May. Under the trust system, health care organizations entrust their pharmacy supply directly to pharmaceutical enterprises to cut expenses. According to statistics from the authorities, drug payment for patients decreased by 10 percent after second-tier hospitals participated in medical trust. Nanjing has established a medical trust center to manage medicine purchasing, drug income and expenses on behalf of nine hospitals. Its specialized central account allows unified billing with drug suppliers, increasing both parties' trust and reducing transaction costs. Analysts say the move represents the government's practical stop-gap approach to address insufficient funding for public hospitals. (Click her for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.